{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:07:21Z","timestamp":1793848041464,"version":"4.6.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["306752\/Z\/23\/Z"],"award-info":[{"award-number":["306752\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["SEBCATP-2022\/100009"],"award-info":[{"award-number":["SEBCATP-2022\/100009"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011717","name":"Leuka","doi-asserted-by":"publisher","award":["2022\/FuF\/001"],"award-info":[{"award-number":["2022\/FuF\/001"]}],"id":[{"id":"10.13039\/100011717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>RNA modifications, collectively termed the epitranscriptome, constitute a dynamic layer of post-transcriptional regulation that governs RNA splicing, stability, localization, translation, and decay. In the hematopoietic system, these chemical marks influence stem cell fate, lineage specification, immune surveillance, and malignant transformation through context-dependent regulation of mRNA, tRNA, rRNA, and non-coding RNAs. Here, we focus on RNA modifications and editing events with emerging mechanistic and translational relevance in normal and malignant hematopoiesis, highlighting those implicated in stem cell dynamics, leukemic progression, and therapeutic resistance. Specifically, we discuss N\u2076-methyladenosine (m\u2076A), 5-methylcytosine (m\u2075C), N\u2077-methylguanosine (m\u2077G), N\u2074-acetylcytidine (ac\u2074C), pseudouridine (\u03a8), adenosine-to-inosine (A-to-I) editing, and RNA glycosylation. Particular attention is given to enzymes such as METTL3, METTL1, ADAR1, and NAT10, whose dysregulation sustains leukemic stem cell programmes, promotes immune evasion, and confers treatment resistance. With the first-in-class METTL3 inhibitor STC-15 now in early-phase clinical trials in solid tumours (NCT05584111, NCT06975293), and additional RNA-modifying enzyme inhibitors advancing preclinically, these pathways are emerging as therapeutically tractable, including in hematological cancers. Furthermore, integrating epitranscriptomic profiles into genomic risk frameworks may also improve disease stratification, minimal residual disease (MRD) monitoring, and the identification of targetable vulnerabilities. Together, these insights position RNA modifications as central to blood cancer biology and support their integration into next-generation diagnostic, prognostic, and therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41375-025-02765-6","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:02:15Z","timestamp":1758301335000},"page":"2848-2857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Epitranscriptomic advances in normal and malignant hematopoiesis"],"prefix":"10.1038","volume":"39","author":[{"given":"Maria","family":"Eleftheriou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-7648","authenticated-orcid":false,"given":"Konstantinos","family":"Tzelepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2765_CR1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/167483a0","volume":"167","author":"WE Cohn","year":"1951","unstructured":"Cohn WE, Volkin E. Nucleoside-5\u2019-phosphates from ribonucleic acid. Nature. 1951;167:483\u20134.","journal-title":"Nature"},{"key":"2765_CR2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187\u20131200.","journal-title":"Cell"},{"key":"2765_CR3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.celrep.2019.07.032","volume":"28","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Luo H, Izzo F, Pickering BF, Nguyen D, Myers R, et al. m(6)A RNA methylation maintains hematopoietic stem cell identity and symmetric commitment. Cell Rep. 2019;28:1703\u20131716.e1706.","journal-title":"Cell Rep"},{"key":"2765_CR4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41556-019-0318-1","volume":"21","author":"H Lee","year":"2019","unstructured":"Lee H, Bao S, Qian Y, Geula S, Leslie J, Zhang C, et al. Stage-specific requirement for Mettl3-dependent m(6)A mRNA methylation during haematopoietic stem cell differentiation. Nat Cell Biol. 2019;21:700\u20139.","journal-title":"Nat Cell Biol"},{"key":"2765_CR5","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.","journal-title":"Mol Cancer"},{"key":"2765_CR6","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X. RNA modification in normal hematopoiesis and hematologic malignancies. MedComm. 2024;5:e787.","journal-title":"MedComm"},{"key":"2765_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Sig Transduct Target Ther. 2021;6:74.","journal-title":"Sig Transduct Target Ther"},{"key":"2765_CR8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MOH.0000000000000636","volume":"28","author":"E Yankova","year":"2021","unstructured":"Yankova E, Aspris D, Tzelepis K. The N6-methyladenosine RNA modification in acute myeloid leukemia. Curr Opin Hematol. 2021;28:80\u201385.","journal-title":"Curr Opin Hematol"},{"key":"2765_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.stem.2021.09.014","volume":"29","author":"R Yin","year":"2022","unstructured":"Yin R, Chang J, Li Y, Gao Z, Qiu Q, Wang Q, et al. Differential m(6)A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. Cell Stem Cell. 2022;29:149\u2013159.e147.","journal-title":"Cell Stem Cell"},{"key":"2765_CR10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.stem.2023.11.006","volume":"30","author":"H Luo","year":"2023","unstructured":"Luo H, Cortes-Lopez M, Tam CL, Xiao M, Wakiro I, Chu KL, et al. SON is an essential m(6)A target for hematopoietic stem cell fate. Cell Stem Cell. 2023;30:1658\u20131673.e1610.","journal-title":"Cell Stem Cell"},{"key":"2765_CR11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature23883","volume":"549","author":"C Zhang","year":"2017","unstructured":"Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017;549:273\u20136.","journal-title":"Nature"},{"key":"2765_CR12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2020.05.003","volume":"52","author":"Y Gao","year":"2020","unstructured":"Gao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, et al. m(6)A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development. Immunity. 2020;52:1007\u20131021.e1008.","journal-title":"Immunity"},{"key":"2765_CR13","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1158\/2159-8290.CD-23-0007","volume":"13","author":"AA Guirguis","year":"2023","unstructured":"Guirguis AA, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan YC, et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov. 2023;13:2228\u201347.","journal-title":"Cancer Discov"},{"key":"2765_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay S, Helm M, Frye M. RNA modifications in physiology and disease: towards clinical applications. Nat Rev Genet. 2024;25:104\u201322.","journal-title":"Nat Rev Genet"},{"key":"2765_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","volume":"62","author":"S Lin","year":"2016","unstructured":"Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335\u201345.","journal-title":"Mol Cell"},{"key":"2765_CR16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson SC, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature. 2017;552:126\u201331.","journal-title":"Nature"},{"key":"2765_CR17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597\u2013601.","journal-title":"Nature"},{"key":"2765_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","volume":"31","author":"Z Li","year":"2017","unstructured":"Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. Cancer Cell. 2017;31:127\u201341.","journal-title":"Cancer Cell"},{"key":"2765_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38:79\u201396.e11.","journal-title":"Cancer Cell"},{"key":"2765_CR20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"2765_CR21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 2024;10:1417\u201325.","journal-title":"JAMA Oncol"},{"key":"2765_CR22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","volume":"22","author":"H Weng","year":"2018","unstructured":"Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. METTL14 inhibits hematopoietic stem\/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018;22:191\u2013205.e199.","journal-title":"Cell Stem Cell"},{"key":"2765_CR23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016;17:1193\u2013205.","journal-title":"Cell Rep"},{"key":"2765_CR24","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41375-022-01696-w","volume":"36","author":"M Li","year":"2022","unstructured":"Li M, Ye J, Xia Y, Li M, Li G, Hu X, et al. METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4. Leukemia. 2022;36:2586\u201395.","journal-title":"Leukemia"},{"key":"2765_CR25","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41375-024-02228-4","volume":"38","author":"WC Hwang","year":"2024","unstructured":"Hwang WC, Park K, Park S, Cheon NY, Lee JY, Hwang T, et al. Impaired binding affinity of YTHDC1 with METTL3\/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation. Leukemia. 2024;38:1353\u201364.","journal-title":"Leukemia"},{"key":"2765_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41588-019-0549-x","volume":"52","author":"A Abakir","year":"2020","unstructured":"Abakir A, Giles TC, Cristini A, Foster JM, Dai N, Starczak M, et al. N(6)-methyladenosine regulates the stability of RNA:DNA hybrids in human cells. Nat Genet. 2020;52:48\u201355.","journal-title":"Nat Genet"},{"key":"2765_CR27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30:52\u201368.e13.","journal-title":"Cell Stem Cell"},{"key":"2765_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2020.04.009","volume":"27","author":"C Shen","year":"2020","unstructured":"Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 2020;27:64\u201380.e69.","journal-title":"Cell Stem Cell"},{"key":"2765_CR29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.stem.2020.04.001","volume":"27","author":"J Wang","year":"2020","unstructured":"Wang J, Li Y, Wang P, Han G, Zhang T, Chang J, et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell. 2020;27:81\u201397.e88.","journal-title":"Cell Stem Cell"},{"key":"2765_CR30","doi-asserted-by":"crossref","unstructured":"Qiao Y, Sun Q, Chen X, He L, Wang D, Su R, et al. Nuclear m6A reader YTHDC1 promotes muscle stem cell activation\/proliferation by regulating mRNA splicing and nuclear export. Elife 2023;12:e82703.","DOI":"10.7554\/eLife.82703"},{"key":"2765_CR31","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ccell.2021.04.017","volume":"39","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, et al. N(6)-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell. 2021;39:958\u2013972.e958.","journal-title":"Cancer Cell"},{"key":"2765_CR32","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood.2021011707","volume":"138","author":"Y Sheng","year":"2021","unstructured":"Sheng Y, Wei J, Yu F, Xu H, Yu C, Wu Q, et al. A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication. Blood. 2021;138:2838\u201352.","journal-title":"Blood"},{"key":"2765_CR33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388\u201399.","journal-title":"Cell"},{"key":"2765_CR34","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen L, Gao Y, Xu S, Yuan J, Wang M, Li T, et al. N6-methyladenosine reader YTHDF family in biological processes: structures, roles, and mechanisms. Front Immunol. 2023;14:1162607.","journal-title":"Front Immunol"},{"key":"2765_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.stem.2019.03.021","volume":"25","author":"J Paris","year":"2019","unstructured":"Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, et al. Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell. 2019;25:137\u2013148.e136.","journal-title":"Cell Stem Cell"},{"key":"2765_CR36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41388-023-02675-w","volume":"42","author":"R Liu","year":"2023","unstructured":"Liu R, Miao J, Jia Y, Kong G, Hong F, Li F, et al. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1\/p21(cip1\/waf1)\/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene. 2023;42:1607\u201319.","journal-title":"Oncogene"},{"key":"2765_CR37","doi-asserted-by":"crossref","unstructured":"Mapperley C, van de Lagemaat LN, Lawson H, Tavosanis A, Paris J, Campos J, et al. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. J Exp Med. 2021;218:e20200829.","DOI":"10.1084\/jem.20200829"},{"key":"2765_CR38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tibs.2024.04.001","volume":"49","author":"Z Zou","year":"2024","unstructured":"Zou Z, He C. The YTHDF proteins display distinct cellular functions on m6A-modified RNA. Trends Biochem Sci. 2024;49:611\u201321.","journal-title":"Trends Biochem Sci"},{"key":"2765_CR39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","volume":"181","author":"S Zaccara","year":"2020","unstructured":"Zaccara S, Jaffrey SR. A unified model for the function of YTHDF proteins in regulating m(6)A-modified mRNA. Cell. 2020;181:1582\u20131595.e1518.","journal-title":"Cell"},{"key":"2765_CR40","volume":"24","author":"Z Zou","year":"2023","unstructured":"Zou Z, Sepich-Poore C, Zhou X, Wei J, He C. The mechanism underlying redundant functions of the YTHDF proteins. Genome Biol. 2023;24:17. 2023\/01\/24.","journal-title":"Genome Biol"},{"key":"2765_CR41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.stem.2022.12.003","volume":"30","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Gao Z, Zhang T, Wang Y, Xie X, Han G, et al. Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell Stem Cell. 2023;30:69\u201385.e67.","journal-title":"Cell Stem Cell"},{"key":"2765_CR42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s12276-022-00735-x","volume":"54","author":"N Zhang","year":"2022","unstructured":"Zhang N, Shen Y, Li H, Chen Y, Zhang P, Lou S, et al. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Exp Mol Med. 2022;54:194\u2013205.","journal-title":"Exp Mol Med"},{"key":"2765_CR43","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","volume":"10","author":"F Pastore","year":"2020","unstructured":"Pastore F, Bhagwat N, Pastore A, Radzisheuskaya A, Karzai A, Krishnan A, et al. PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-mutant MPN. Cancer Discov. 2020;10:1742\u201357.","journal-title":"Cancer Discov"},{"key":"2765_CR44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","volume":"36","author":"JY Fong","year":"2019","unstructured":"Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36:194\u2013209.e199.","journal-title":"Cancer Cell"},{"key":"2765_CR45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2020009676","volume":"138","author":"M Feng","year":"2021","unstructured":"Feng M, Xie X, Han G, Zhang T, Li Y, Li Y, et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021;138:71\u201385.","journal-title":"Blood"},{"key":"2765_CR46","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41556-023-01213-w","volume":"25","author":"X Dou","year":"2023","unstructured":"Dou X, Xiao Y, Shen C, Wang K, Wu T, Liu C, et al. RBFOX2 recognizes N(6)-methyladenosine to suppress transcription and block myeloid leukaemia differentiation. Nat Cell Biol. 2023;25:1359\u201368.","journal-title":"Nat Cell Biol"},{"key":"2765_CR47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/s41556-023-01205-w","volume":"25","author":"J Russell","year":"2023","unstructured":"Russell J, Tzelepis K. A non-coding m(6)A reader promotes leukaemia. Nat Cell Biol. 2023;25:1247\u20139.","journal-title":"Nat Cell Biol"},{"key":"2765_CR48","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1021\/acs.jmedchem.1c00773","volume":"64","author":"A Dolbois","year":"2021","unstructured":"Dolbois A, Bedi RK, Bochenkova E, Muller A, Moroz-Omori EV, Huang D, et al. 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. J Med Chem. 2021;64:12738\u201360.","journal-title":"J Med Chem"},{"key":"2765_CR49","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41375-023-01965-2","volume":"37","author":"K Sturgess","year":"2023","unstructured":"Sturgess K, Yankova E, Vijayabaskar MS, Isobe T, Rak J, Kucinski I, et al. Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages. Leukemia. 2023;37:2133\u20137.","journal-title":"Leukemia"},{"key":"2765_CR50","doi-asserted-by":"crossref","unstructured":"Moser JC, Papadopoulos KP, Rodon Ahnert J, Ofir-Rosenfeld Y, Holz J-B. Phase 1doseescalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies. ASCO J Clin Oncol. 2024.","DOI":"10.1136\/jitc-2024-SITC2024.0676"},{"key":"2765_CR51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","volume":"35","author":"Y Huang","year":"2019","unstructured":"Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35:677\u2013691.e610.","journal-title":"Cancer Cell"},{"key":"2765_CR52","doi-asserted-by":"crossref","unstructured":"Coller J, Gkatza NA, Castro C, Harvey RF, Hei\u00df M, Popis MC, et al. Cytosine-5 RNA methylation links protein synthesis to cell metabolism. PLOS Biol. 2019;17:e3000297.","DOI":"10.1371\/journal.pbio.3000297"},{"key":"2765_CR53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature18282","volume":"534","author":"S Blanco","year":"2016","unstructured":"Blanco S, Bandiera R, Popis M, Hussain S, Lombard P, Aleksic J, et al. Stem cell function and stress response are controlled by protein synthesis. Nature. 2016;534:335\u201340.","journal-title":"Nature"},{"key":"2765_CR54","doi-asserted-by":"crossref","unstructured":"Li S, Liu Y, Wu X, Pan M, Zhao H, Hong Y, et al. The m\u2075C methyltransferase NSUN2 promotes progression of acute myeloid leukemia by regulating serine metabolism. Cell Rep. 2025;44:115661.","DOI":"10.1016\/j.celrep.2025.115661"},{"key":"2765_CR55","first-page":"6125","volume":"13","author":"L Zheng","year":"2023","unstructured":"Zheng L, Duan Y, Li M, Wei J, Xue C, Chen S, et al. Deciphering the vital roles and mechanism of m5C modification on RNA in cancers. Am J Cancer Res. 2023;13:6125\u201346.","journal-title":"Am J Cancer Res"},{"key":"2765_CR56","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.62347\/NXDR1826","volume":"14","author":"W Cui","year":"2024","unstructured":"Cui W, Luo C, Zhou L, Yu T, Meng Y, Yu Q, et al. Roles of RNA m(5)C modification patterns in prognosis and tumor microenvironment infiltration of diffuse large B-cell lymphoma. Am J Cancer Res. 2024;14:1768\u201383.","journal-title":"Am J Cancer Res"},{"key":"2765_CR57","volume":"9","author":"JX Cheng","year":"2018","unstructured":"Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018;9:1163.","journal-title":"Nat Commun"},{"key":"2765_CR58","doi-asserted-by":"crossref","unstructured":"Bonner EA, Lee SC. Therapeutic targeting of RNA splicing in cancer. Genes. 2023;14:1378.","DOI":"10.3390\/genes14071378"},{"key":"2765_CR59","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","volume":"120","author":"M Meggendorfer","year":"2012","unstructured":"Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120:3080\u20138.","journal-title":"Blood"},{"key":"2765_CR60","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.molcel.2023.11.003","volume":"83","author":"HL Ma","year":"2023","unstructured":"Ma HL, Bizet M, Soares Da Costa C, Murisier F, de Bony EJ, Wang MK, et al. SRSF2 plays an unexpected role as reader of m(5)C on mRNA, linking epitranscriptomics to cancer. Mol Cell. 2023;83:4239\u20134254.e4210.","journal-title":"Mol Cell"},{"key":"2765_CR61","volume":"16","author":"Q Gao","year":"2024","unstructured":"Gao Q, Shen K, Xiao M. TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights. Clin Epigenet. 2024;16:155.","journal-title":"Clin Epigenet"},{"key":"2765_CR62","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00739-w","volume":"12","author":"F Huang","year":"2022","unstructured":"Huang F, Sun J, Chen W, Zhang L, He X, Dong H, et al. TET2 deficiency promotes MDS-associated leukemogenesis. Blood Cancer J. 2022;12:141.","journal-title":"Blood Cancer J"},{"key":"2765_CR63","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"WC Chou","year":"2011","unstructured":"Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:3803\u201310.","journal-title":"Blood"},{"key":"2765_CR64","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","volume":"118","author":"Z Li","year":"2011","unstructured":"Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118:4509\u201318.","journal-title":"Blood"},{"key":"2765_CR65","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.stem.2023.07.001","volume":"30","author":"Y Li","year":"2023","unstructured":"Li Y, Xue M, Deng X, Dong L, Nguyen LXT, Ren L, et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 2023;30:1072\u201390.e1010.","journal-title":"Cell Stem Cell"},{"key":"2765_CR66","volume":"121","author":"R Wu","year":"2024","unstructured":"Wu R, Sun C, Chen X, Yang R, Luan Y, Zhao X, et al. NSUN5\/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. Proc Natl Acad Sci USA. 2024;121:e2321611121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2765_CR67","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41586-024-07969-x","volume":"634","author":"Z Zou","year":"2024","unstructured":"Zou Z, Dou X, Li Y, Zhang Z, Wang J, Gao B, et al. RNA m(5)C oxidation by TET2 regulates chromatin state and leukaemogenesis. Nature. 2024;634:986\u201394.","journal-title":"Nature"},{"key":"2765_CR68","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44:7511\u201326.","journal-title":"Nucleic Acids Res"},{"key":"2765_CR69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-022-01285-5","volume":"15","author":"Y Luo","year":"2022","unstructured":"Luo Y, Yao Y, Wu P, Zi X, Sun N, He J. The potential role of N(7)-methylguanosine (m7G) in cancer. J Hematol Oncol. 2022;15:63.","journal-title":"J Hematol Oncol"},{"key":"2765_CR70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-024-00477-8","volume":"13","author":"P Zhao","year":"2024","unstructured":"Zhao P, Xia L, Chen D, Xu W, Guo H, Xu Y, et al. METTL1 mediated tRNA m(7)G modification promotes leukaemogenesis of AML via tRNA regulated translational control. Exp Hematol Oncol. 2024;13:8.","journal-title":"Exp Hematol Oncol"},{"key":"2765_CR71","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1016\/j.molcel.2021.06.031","volume":"81","author":"EA Orellana","year":"2021","unstructured":"Orellana EA, Liu Q, Yankova E, Pirouz M, De Braekeleer E, Zhang W, et al. METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation. Mol Cell. 2021;81:3323\u20133338.e3314.","journal-title":"Mol Cell"},{"key":"2765_CR72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOH.0000000000000692","volume":"29","author":"S Mishra","year":"2022","unstructured":"Mishra S, Liu J, Chai L, Tenen DG. Diverse functions of long noncoding RNAs in acute myeloid leukemia: emerging roles in pathophysiology, prognosis, and treatment resistance. Curr Opin Hematol. 2022;29:34\u201343.","journal-title":"Curr Opin Hematol"},{"key":"2765_CR73","volume":"24","author":"J Han","year":"2023","unstructured":"Han J, Liu Q, Zhou Y, Li D, Wang R. Landscape of internal N7-methylguanosine of long non-coding RNA modifications in resistant acute myeloid leukemia. BMC Genom. 2023;24:425.","journal-title":"BMC Genom"},{"key":"2765_CR74","volume":"13","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wen R, Wu G, Li G, Wu X, Guo Y, et al. Identification and validation of a prognostic risk-scoring model for AML based on m(7)G-associated gene clustering. Front Oncol. 2023;13:1301236.","journal-title":"Front Oncol"},{"key":"2765_CR75","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00392-2","volume":"10","author":"F Deng","year":"2022","unstructured":"Deng F, Zhang C, Lu T, Liao EJ, Huang H, Wei S. Roles of circRNAs in hematological malignancies. Biomark Res. 2022;10:50.","journal-title":"Biomark Res"},{"key":"2765_CR76","volume":"13","author":"J Fu","year":"2023","unstructured":"Fu J, Si L, Zhou Y, Li D, Wang R. Distinct N7-methylguanosine profiles of circular RNAs in drug-resistant acute myeloid leukemia. Sci Rep. 2023;13:14704.","journal-title":"Sci Rep"},{"key":"2765_CR77","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.cell.2018.10.030","volume":"175","author":"D Arango","year":"2018","unstructured":"Arango D, Sturgill D, Alhusaini N, Dillman A, Sweet TJ, Hanson G, et al. Acetylation of cytidine in mRNA promotes translation efficiency. Cell. 2018;175:1872\u20131886.e1824.","journal-title":"Cell"},{"key":"2765_CR78","volume":"14","author":"Q Yan","year":"2023","unstructured":"Yan Q, Zhou J, Wang Z, Ding X, Ma X, Li W, et al. NAT10-dependent N4-acetylcytidine modification mediates PAN RNA stability, KSHV reactivation, and IFI16-related inflammasome activation. Nat Commun. 2023;14:6327.","journal-title":"Nat Commun"},{"key":"2765_CR79","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/emboj.2008.154","volume":"27","author":"Y Ikeuchi","year":"2008","unstructured":"Ikeuchi Y, Kitahara K, Suzuki T. The RNA acetyltransferase driven by ATP hydrolysis synthesizes N4-acetylcytidine of tRNA anticodon. EMBO J. 2008;27:2194\u2013203.","journal-title":"EMBO J"},{"key":"2765_CR80","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2019.06.006","volume":"44","author":"P Liang","year":"2020","unstructured":"Liang P, Hu R, Liu Z, Miao M, Jiang H, Li C. NAT10 upregulation indicates a poor prognosis in acute myeloid leukemia. Curr Probl Cancer. 2020;44:100491.","journal-title":"Curr Probl Cancer"},{"key":"2765_CR81","volume":"10","author":"J Zi","year":"2020","unstructured":"Zi J, Han Q, Gu S, McGrath M, Kane S, Song C, et al. Targeting NAT10 induces apoptosis associated with enhancing endoplasmic reticulum stress in acute myeloid leukemia cells. Front Oncol. 2020;10:598107.","journal-title":"Front Oncol"},{"key":"2765_CR82","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"2765_CR83","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.apsb.2022.01.015","volume":"12","author":"R Wei","year":"2022","unstructured":"Wei R, Cui X, Min J, Lin Z, Zhou Y, Guo M, et al. NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma. Acta Pharm Sin B. 2022;12:3313\u201325.","journal-title":"Acta Pharm Sin B"},{"key":"2765_CR84","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Deng Z, Sun S, Xie S, Jiang M, Chen B, et al. NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway. Front Oncol. 2022;12:967811.","journal-title":"Front Oncol"},{"key":"2765_CR85","doi-asserted-by":"crossref","first-page":"e101971","DOI":"10.1371\/journal.pone.0101971","volume":"9","author":"L Rocchi","year":"2014","unstructured":"Rocchi L, Barbosa AJ, Onofrillo C, Del Rio A, Montanaro L. Inhibition of human dyskerin as a new approach to target ribosome biogenesis. PLoS One. 2014;9:e101971.","journal-title":"PLoS One"},{"key":"2765_CR86","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood-2007-09-111245","volume":"111","author":"D Poncet","year":"2008","unstructured":"Poncet D, Belleville A, t\u2019kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood. 2008;111:2388\u201391.","journal-title":"Blood"},{"key":"2765_CR87","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2018.03.008","volume":"173","author":"N Guzzi","year":"2018","unstructured":"Guzzi N, Ciesla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, et al. Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. Cell. 2018;173:1204\u20131216.e1226.","journal-title":"Cell"},{"key":"2765_CR88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41556-022-00852-9","volume":"24","author":"N Guzzi","year":"2022","unstructured":"Guzzi N, Muthukumar S, Ciesla M, Todisco G, Ngoc PCT, Madej M, et al. Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. Nat Cell Biol. 2022;24:299\u2013306.","journal-title":"Nat Cell Biol"},{"key":"2765_CR89","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.celrep.2013.04.030","volume":"3","author":"C Bellodi","year":"2013","unstructured":"Bellodi C, McMahon M, Contreras A, Juliano D, Kopmar N, Nakamura T, et al. H\/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation. Cell Rep. 2013;3:1493\u2013502.","journal-title":"Cell Rep"},{"key":"2765_CR90","doi-asserted-by":"crossref","DOI":"10.1186\/gm508","volume":"5","author":"W Slotkin","year":"2013","unstructured":"Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5:105.","journal-title":"Genome Med"},{"key":"2765_CR91","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc.2017.23","volume":"17","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Crews LA, Holm F, Jamieson CHM. RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer. 2017;17:381\u201392.","journal-title":"Nat Rev Cancer"},{"key":"2765_CR92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.stem.2016.05.004","volume":"19","author":"MA Zipeto","year":"2016","unstructured":"Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis. Cell Stem Cell. 2016;19:177\u201391.","journal-title":"Cell Stem Cell"},{"key":"2765_CR93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccell.2018.11.017","volume":"35","author":"Jiang","year":"2019","unstructured":"Jiang, Isquith Q, Zipeto MA J, Diep RH, Pham J, Delos Santos N, et al. Hyper-editing of cell-cycle regulatory and tumor suppressor RNA promotes malignant progenitor propagation. Cancer Cell. 2019;35:81\u201394.e87.","journal-title":"Cancer Cell"},{"key":"2765_CR94","volume":"34","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Isquith J, Ladel L, Mark A, Holm F, Mason C, et al. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Rep. 2021;34:108670.","journal-title":"Cell Rep"},{"key":"2765_CR95","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113704","volume":"43","author":"M Rivera","year":"2024","unstructured":"Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Balaian L, et al. Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell Rep. 2024;43:113704.","journal-title":"Cell Rep"},{"key":"2765_CR96","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.cell.2021.04.023","volume":"184","author":"RA Flynn","year":"2021","unstructured":"Flynn RA, Pedram K, Malaker SA, Batista PJ, Smith BAH, Johnson AG, et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell. 2021;184:3109\u20133124.e3122.","journal-title":"Cell"},{"key":"2765_CR97","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2023.12.033","volume":"187","author":"N Zhang","year":"2024","unstructured":"Zhang N, Tang W, Torres L, Wang X, Ajaj Y, Zhu L, et al. Cell surface RNAs control neutrophil recruitment. Cell. 2024;187:846\u2013860.e817.","journal-title":"Cell"},{"key":"2765_CR98","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.cell.2025.01.040","volume":"188","author":"J Perr","year":"2025","unstructured":"Perr J, Langen A, Almahayni K, Nestola G, Chai P, Lebedenko CG, et al. RNA-binding proteins and glycoRNAs form domains on the cell surface for cell-penetrating peptide entry. Cell. 2025;188:1878\u20131895.e1825.","journal-title":"Cell"},{"key":"2765_CR99","doi-asserted-by":"crossref","unstructured":"George BM, Eleftheriou M, Yankova E, Perr J, Chai P, Nestola G, et al. Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein. Nat Biotechnol. 2025. Online ahead of print.","DOI":"10.1038\/s41587-025-02648-2"},{"key":"2765_CR100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.11007","volume":"92","author":"B Falini","year":"2007","unstructured":"Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92:519\u201332.","journal-title":"Haematologica"},{"key":"2765_CR101","first-page":"2023","volume":"14","author":"Z Li","year":"2023","unstructured":"Li Z, Liu X, Wang L, Zhao H, Wang S, Yu G, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia. Front Immunol. 2023;14:2023.","journal-title":"Front Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02765-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:57Z","timestamp":1763629857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02765-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02765-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KT has received stock options and research funding from Storm Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}